GLP-1 Receptor Agonists

Phase 1Small molecule

GLP-1 Receptor Agonists is one of 59 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Ovary SyndromeActive, not recruiting

LymphedemaActive, not recruiting

Polycystic Ovary SyndromePreclinical

Active, not recruiting

LymphedemaPhase 1

Active, not recruiting

Competition

Competitive Landscape

175 competitors in Polycystic Ovary Syndrome

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

1 2

Glucophage

Boehringer Ingelheim

Phase 3

2 3

Decadron

AAspen Global Incorporated

Phase 3

2 4

DLBS3233

DDexa Medica Group

Phase 3

1 5

Clomid

Ferring

Preclinical

13 6

Precose

Bayer

Preclinical

2 7

Proglycem

Teva

Preclinical

1 8

Clomid

EMD Serono

Preclinical

3 9

Cetrotide

EMD Serono

Preclinical

3 10

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Polycystic Ovary Syndrome

NCT07169136

Q2 2027

Phase 1Recruiting

Lymphedema

NCT07012642

Clinical

Trials by Indication[1]

Lymphedema1 trial

Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

Recruiting·AAdvanced Reconstructive Surgery Alliance·Phase 1·NCT07012642·110 enrolled

Polycystic Ovary Syndrome1 trial

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

Recruiting·NNemours Children's Clinic··NCT07169136·20 enrolled

PCOS1 trial

Research of Intensive Lifestyle Intervention for PCOS Patients With IGT

Completed·RRenJi Hospital·N/A·NCT02446834·40 enrolled

Function1 trial

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

Not yet recruiting·JJinling Hospital, China·N/A·NCT07297238·20 enrolled

Alzheimer disease1 trial

GLP-1 Receptor Agonists Prevent Alzheimer's Disease Onset, Not Progression: Resolving the Real-World-Randomised Trial Paradox Across Five Continents

Completed·WWest China Hospital··NCT07677865·213,891 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GLP-1 Receptor Agonists. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP-1 Receptor Agonists compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP-1 Receptor Agonists. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jinling Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJinling Hospital, China

GLP-1 Receptor Agonists

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Lymphedema1 trial

Polycystic Ovary Syndrome1 trial

PCOS1 trial

Function1 trial

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News